

Table 7  
(Continued)

Treatment goal	Target	Drug	Company	Stage	Reference	Location
Anti-inflammatory	Live biotherapeutic product	MRx-4DP0004	4D Pharma	Phase II	[316]	United Kingdom
Anti-inflammatory	XPO1 inhibitor	Xpovio	Karyopharm Therapeutics	Phase II	[317]	USA
Anti-inflammatory	Opioid antagonist	Naltrexone	Beaumont Health	Phase II	[318]	USA
Anti-inflammatory	NMDA antagonist	Ketamine	Beaumont Health	Phase II	[318]	USA
Anti-inflammatory	BTK inhibitor	Brukina	BeiGene	Phase II	[319]	USA
Anti-inflammatory	BTK inhibitor	Calquence	Astrazeneca	Phase II	[320, 321]	Multiple locations
Anti-inflammatory	HMGB1 inhibitor	DSTAT	Chimerix	Phase II/III	[322]	USA
Anti-inflammatory	Recombinant humanized GM-CSF	Leukine	Partner therapeutics	Phase IV	[323]	Belgium
Anti-inflammatory	Upregulate RNA splicing	ABX464	Abivax	Phase II/III	[324]	France
Anti-inflammatory	IL-6 inhibitor mAb	Clazakizumab	Vitaeris	Phase II	[325]	USA
Anti-inflammatory	Anti- IL-8 mAb	BMS-986253	Bristol Myers Squibb	Phase II	[326]	USA
Anti-inflammatory	IL-6 inhibitor	Sirukumab	Janssen	Phase II	[327]	USA
Anti-inflammatory	IL-6 inhibitor	Actemra	Roche	Phase III	[328-331]	Multiple locations
Anti-inflammatory	IL-6 inhibitor	CD24Fc	Oncoimmune	Phase III	[332]	USA
Anti-inflammatory	IL-6 inhibitor	Kevzara	Regeneron, Sanofi	Phase II/III	[333]	Multiple locations
Anti-inflammatory	IL-6 inhibitor	Aviptadil	NeuroRX, relief therapeutics	Phase II	[334]	USA
Anti-inflammatory	IL-6 inhibitor	Sylvant	EUSA Pharma	Phase III	[335, 336]	Multiple locations
Anti-inflammatory	IL-6 inhibitor	Levilimab	Biocad	Phase III	[337]	Russian Federation
Anti-inflammatory	IL-6 inhibitor	Olokizumab	R-Pharm	Phase II/III	[338]	Russian Federation
Anti-inflammatory	IL-7 agonist	CYT107	RevImmune	Phase II	[339]	United Kingdom
Anti-inflammatory	TLR 7/8 antagonist	M5049	Merck KGaA	Phase II	[340]	USA
Anti-inflammatory	Anti – GM -CSF	Lenzilumab	Humanigen	Phase III	[341]	USA
Anti-inflammatory	Anti – GM -CSF	Gimsilumab	Roivant, Altasciences	Phase II	[342]	USA
bAnti-inflammatory	Turbulin disruption	Colchicine	Montreal Heart Institute	Phase III	[343]	Canada
Anti-inflammatory	NK1 inhibitor	Tradipitant	Vanda Pharmaceuticals	Phase III	[344]	USA
Anti-inflammatory	C5a mAb	IFX-1	InflaRX	Phase II/III	[345]	Netherlands
Anti-inflammatory	IL-1 inhibitor	Kineret	Sobi	Phase III	[346]	Italy
Anti-inflammatory	IL-1B inhibitor	RPH-104	R-Pharm	Phase II/III	[338]	Russia
Anti-inflammatory	IL-15 superagonist	N-803	ImmunityBio	Phase I	[347]	USA
Anti-inflammatory	IFN $\gamma$ mAb	Gamifant	Sobi	Phase II/III	[346]	Italy
Anti-inflammatory	CGRP receptor antagonist	Vazegepant	Biohaven Pharma	Phase II/III	[348]	USA
Anti-inflammatory	CCR5 antagonist	Leronlimab (PRO 140)	CytoDyn	Phase II	[349]	USA
Anti-inflammatory	Sphingosine 1-phosphate receptor modulator	Gilenya	Novartis	Phase II	[350]	China
Anti-inflammatory	Tissue regeneration	Mesenchymal Stem cells	Multiple companies	Phase II	[351–365]	Multiple locations
Anti-inflammatory	Mesenchymal Stem cells	RYONCIL	Mesoblast	Phase III	[366]	USA
Anti-inflammatory	A3 adenosine receptor agonist	Piclidenoson	Can-Fite Biopharma	Phase II	[367]	Israel
Anti-inflammatory	Jak2, IRAK-1, CSF1R inhibitors	Pacritinib	CTI Biopharma	Phase III	[368]	USA